Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ☆
Titel:
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ☆
Auteur:
Martin, M. Zielinski, C. Ruiz-Borrego, M. Carrasco, E. Turner, N. Ciruelos, E.M. Muñoz, M. Bermejo, B. Margeli, M. Anton, A. Kahan, Z. Csöszi, T. Casas, M.I. Murillo, L. Morales, S. Alba, E. Gal-Yam, E. Guerrero-Zotano, A. Calvo, L. de la Haba-Rodriguez, J. Ramos, M. Alvarez, I. Garcia-Palomo, A. Huang Bartlett, C. Koehler, M. Caballero, R. Corsaro, M. Huang, X. Garcia-Sáenz, J.A. Chacón, J.I. Swift, C. Thallinger, C. Gil-Gil, M.